VascVersa completes second investment round

VascVersa completes second investment round to accelerate development of ground-breaking cell therapies.

• VascVersa, a spin-out from the Queen’s University Belfast, has secured its second funding round, raising over £0.5 million.

• VascVersa is developing a new class of cell therapy, Angicyte, which promotes the creation of new blood vessels.

• Target patient groups include diabetic patients suffering from non-healing foot ulcers – which cost the NHS over £1 billion a year.